The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from ...

By Patrick Wingrove (Reuters) -Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of ...

Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year ...